Standigm
Seoul
About Standigm
Standigm is a workflow AI-driven drug discovery company. Standigm has proprietary AI platforms encompassing novel target identification to lead generation to generate commercially valuable drug pipelines. Founded in 2015, the company has established an early-stage drug discovery workflow AI to generate First-in-Class lead compounds within seven months. Pursuing full-stack, AI-driven industrializing drug discovery, Standigm has achieved the automation of molecular design workflow through DarkMolFactory™, and the automation effort has been expanding to the whole drug discovery process on the basis of Standigm AI platforms, including Standigm ASK™ for target discovery, Standigm BEST™ for lead design, and Standigm Insight™ for drug repurposing.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 51 – 100
- Estimated revenue: $1K – $10K
- Total funding: $71.5M
- Funding stage: Late Stage Venture
- Last round: Series D (Jun 2021)
- Website: standigm.com
- Phone: 82-2-501-8118
Industries & Categories
Artificial Intelligence (AI), Biotechnology, Health Care, Machine Learning, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/standigm-51456 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.